ADMA (ADMA Biologics) Total Equity: $390.3 Mil (As of Mar. 2026)


ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.73
GF Value $17.95
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Total Equity?

ADMA Biologics ADMA +0.34% 64 Total Equity is $390.3 Mil as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $17.95 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ADMA Biologics's total equity for the quarter that ended in Mar. 2026 was $390.3 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ADMA Biologics Total Equity Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Total Equity Chart

ADMA Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 141.17 151.97 135.21 349.02 477.32

ADMA Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 373.42 398.33 431.19 477.32 390.33
ADMA
64GF Score
ADMA Biologics Inc ADMA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ADMA Biologics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=624.242-146.922
=477.3

ADMA Biologics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=665.184-274.859
=390.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $390.3 Mil mean?
ADMA Biologics (ADMA) has a Total Equity of $390.3 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for ADMA Biologics and its competitors.
Is ADMA Biologics' Total Equity too high?
ADMA Biologics' current Total Equity is $390.3 Mil. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Total Equity compare to ZYME and NRIX?
ADMA Biologics' Total Equity of $390.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for ADMA Biologics and its competitors. ADMA Biologics's current Total Equity is $390.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.95, compared to a current price of $8.73 — trading 51.4% below its estimated fair value. The current Total Equity is $390.3 Mil. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Total Equity is $390.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.73 is trading 51.4% below its estimated GF Value™ of $17.95. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Total Equity: $390.3 Mil
  • GF Value™: $17.95 vs. price of $8.73 (51.4% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.73
Price
$17.95
GF Value